Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 17:36 ET
|
Unicycive Therapeutics, Inc.
Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA...
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
July 20, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
July 18, 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...